USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04425850|
Recruitment Status : Completed
First Posted : June 11, 2020
Results First Posted : October 19, 2020
Last Update Posted : October 19, 2020
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.
It is estimated that 86% of all infections were undocumented [95% credible interval (CI): 82-90%] before the 23 January 2020 travel restrictions. The transmission rate of undocumented infections per person was 55% the transmission rate of documented infections (95% CI: 46-62%), yet, because of their greater numbers, undocumented infections were the source of 79% of the documented cases.
Ivermectin + Carrageenan, taking advantage of their virucidal effects, are aimed at reducing the contagion.
|Condition or disease||Intervention/treatment|
|Covid19||Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)|
|Study Type :||Observational|
|Actual Enrollment :||229 participants|
|Official Title:||USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid Among Healthy People and Health Personnel|
|Actual Study Start Date :||June 1, 2020|
|Actual Primary Completion Date :||August 10, 2020|
|Actual Study Completion Date :||August 10, 2020|
Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
Combination Product: Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)
Topical application in the nose and oral cavity
Other Name: Nasitral (iota carrageenan nasal spray), Ivercass (ivermectin oral drops)
Adults, both genders, no age limit They will follow standard prophylactic measures and use PPE suggestions, only.
- Number of Infected Subjects [ Time Frame: 28 days ]Number of participants testing positive for COVID-19 after inclusion in each arm
- Adverse Events Other Than Those Resulting From Contagion or Disease Progression [ Time Frame: 28 days ]Adverse events reported by subjects of each arm are recorded other than those resulting from contagion or disease progression
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04425850
|Buenos Aires, Argentina, 1802|